CTE 1.82% $1.12 cryosite limited

Ann: Change in substantial holding, page-4

  1. 1,173 Posts.
    lightbulb Created with Sketch. 588
    "...has a newsletter recommended them?"

    I don't know @gmac, but I can understand why an astute newsletter editor might be focussing on CTE:

    1. Uncertainty about Cell Care sell-down depressing the SP now removed;

    2. New substantial shareholder announcement imminent;

    3. Company share-buy back scheme to start in mid-April;

    4. Cash backing of $4.3m;

    5. Enterprise value at a humble ~$6m;

    6. No debt;

    7. First half revenue up 18.5% after a 30% rise in clinical trials revenue;

    8. Pivotal and unique moated exposure to the national clinical trials industry and the exploding medicinal cannabis market.

    And all of this for a stock that's ~50% below its 52 week high. Conclusion: I see scope for material improvement in the SP.
    Last edited by Medify: 12/03/21
 
watchlist Created with Sketch. Add CTE (ASX) to my watchlist
(20min delay)
Last
$1.12
Change
0.020(1.82%)
Mkt cap ! $54.66M
Open High Low Value Volume
$1.12 $1.12 $1.12 $409 365

Buyers (Bids)

No. Vol. Price($)
1 33 $1.12
 

Sellers (Offers)

Price($) Vol. No.
$1.15 10000 1
View Market Depth
Last trade - 11.00am 24/06/2024 (20 minute delay) ?
CTE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.